New England Journal of Medicine on Rosiglitazone (Avandia) Medication

The New England Journal of Medicine has just released a study examining the link between the medication Rosiglitazone (marketed as Avandia, Avandamet, and Avandaryl) and cardiovascular problems such as heart attacks.

The study, which appears in the June 14, 2007 issue of the journal, analyzes over 40 existing clinical studies involving nearly 28,000 patients.

The authors concluded that Avandia significantly increased the risk of heart attacks, compared with other diabetes drugs or a placebo.

In the study's conclusions, the authors wrote that "patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes."

In an interview with the New York Times, the study's lead author, Dr. Steven E. Nissen of the Cleveland Clinic, said that the average diabetic had a 20.2 percent risk of a heart attack over a seven-year period. "A diabetic taking Avandia," said Nissen, "has a 28.9 percent risk during that same seven-year time period," according to his analysis.

The research method used by Nissen and his colleagues, was a "meta-analysis," which combines the data of numerous studies.

If you or a loved one has suffered cardiac complications after ingesting Avandia, you deserve the guidance of an experienced drug attorney. Get a free case review by filling out the form below.

Click To Talk To Us Online

see also:

NEJM Update, 6.5.07 Leading Medical Journal Prints Article on Avandia Drug Side Effects
Further Questions Revealed on Avandia Drug Side Effects, Says Journal

NEJM Study New England Journal of Medicine on Rosiglitazone (Avandia) Medication
Study on Rosiglitazone (Avandia) Medication and Risk of Cardiac Issues

News & Warnings Avandia Breaking News: Glaxo Warned in 2001 about Misleading Marketing
Bloomberg News: FDA Warned Glaxo about Avandia Marketing in 2001